| 2006 - 2010 | Type 2 diabetes and lifestyle in ethnic minorities in Oslo, and in populations in Pakistan, Bangladesh and China | Akhtar Hussain |
| 2010 - 2014 | Molecular control of T cell memory | Anne Spurkland |
| 2008 - 2012 | HIV vulnerability and HIV prevention needs among men who have sex with men in Tanzania | Anne-Lise Middelthon |
| 2008 - 2011 | Accessibility to health services among people with disabilities in southern Africa | Arne Henning Eide |
| 2006 - 2012 | Strengthening human resources for health. A study of health worker availability and performance in Tanzania | Astrid Blystad |
| 2009 - 2013 | Application of Open Source Licensing to Vaccine and Medicine Discovery and Development | Atle Fretheim |
| 2006 - 2011 | Pectin products from Malian medicinal plants, can they combat ailments related to the immune system? | Berit Smestad Paulsen |
| 2008 - 2013 | 2nd generation Vaccibodies for infectious diseases | Bjarne Bogen |
| 2007 - 2011 | Novel vaccine candidates and delivery systems for HIV and influenza | Bjarne Bogen |
| 2009 - 2013 | A rapid serological screening method for detecting tuberculosis disease and monitoring the efficacy of new vaccines | Carol Holm-Hansen |
| 2007 - 2013 | Further Developments of New Immunogenic Peptide-based HIV Vaccines Targeting Dendritic Cells | Dag Kvale |
| 2009 - 2013 | Improved vaccination responses and optional immunomodulating therapy by adjuvant administration of COX-2 inhibitor in HIV-infect | Dag Kvale |
| 2006 - 2010 | Alternative Treatment Strategies in HIV Infection - research platform with integrated biological and clinical objectives | Dag Kvale |
| 2008 - 2011 | Impact of a new and affordable conjugate meningococcal vaccine on carriage of serogroup A Neisseria meningitidis and disease tra | Dominique A. Caugant |
| 2010 - 2012 | Additional activities related to an ongoing project: Impact of the new vaccine MenAfriVac on carriage of serogroup A Neisseria m | Dominique A. Caugant |
| 2007 - 2012 | New rotavirus vaccines: targeting childhood morbidity and mortality in low- and middle-income countries in Central Asia | Elmira Flem |
| 2010 - 2015 | Target cell recognition by natural killer cells | Erik Dissen |
| 2012 - 2014 | Development of biodegradable nanobeads as vaccines against tuberculosis. | Gareth Griffiths |
| 2004 - 2008 | Tuberculosis in the 21st century; an emerging pandemic | Gunnar Aksel Bjune |
| 2010 - 2013 | Studies of humoral and cell-mediated protective immune markers during Mycobacterium tuberculosis infection in human population | Gunnar Aksel Bjune |
| 2007 - 2007 | Project establishment: Development of vaccine(s) against infections with diarrheagenic Escherichia coli and Shigella | Halvor Sommerfelt |
| 2008 - 2012 | Evaluation of the Impact of the Integrated Management of Neonatal and Childhood Illness Strategy on Neonatal and Infant Mortalit | Halvor Sommerfelt |
| 2008 - 2013 | Developing vaccines against diarrhea caused by Enterotoxigenic Escherichia coli and Shigella (EntVac) | Halvor Sommerfelt |
| 2006 - 2009 | Development of a subunit vaccine for prevention of reactivation of tuberculosis | Harald G. Wiker |
| 2009 - 2013 | Development of novel vaccine candidates to prevent primary or reactivated tuberculosis | Harald G. Wiker |
| 2007 - 2013 | Preparing for tuberculosis vaccine efficacy trials: Baseline epidemiology, improved diagnosis, markers of protection and phase I | Harleen Grewal |
| 2012 - 2014 | Preparing for tuberculosis vaccine efficacy trials: Identifying at-risk individuals for TB vaccine trials. | Harleen Grewal |
| 2008 - 2012 | IMPROVING DIAGNOSIS, TREATMENT AND CONTROL OF CHILDHOOD TUBERCULOSIS | Harleen Grewal |
| 2006 - 2008 | Development and validation of delivery technology for gene based prophylactic vaccines | Iacob Mathiesen |
| 2007 - 2012 | LAYVAC: Lay health worker programmes for vaccine uptake in low and middle income countries: Developing a global knowledge-base | Inger Brummenæs Scheel |
